Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

I-Mab Announces Dosing of First Patient in a Phase I Clinical Trial of TJC4

americanpharmaceuticalreviewJune 26, 2019

Tag: CD47 , clinical trial , First patient , I-Mab

PharmaSources Customer Service